Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Klozapin Ebb

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C C
C C

Klozapin Testmiljö

Klozapin

Klass : C

Visa all info

Skriv ut

Kontakta oss

  1. Leponex (klozapin). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2019-09-22, cited 2020-08-25]

  2. Krivoy A, Gaughran F, Weizman A, Breen G, MacCabe JH. Gene polymorphisms potentially related to the pharmacokinetics of clozapine: a systematic review. Int Clin Psychopharmacol. 2016;31(4):179-84.

  3. Eiermann B, Engel G, Johansson I, Zanger UM, Bertilsson L. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol. 1997;44(5):439-46.

  4. Albitar O, Harun SN, Zainal H, Ibrahim B, Sheikh Ghadzi SM. Population Pharmacokinetics of Clozapine: A Systematic Review. Biomed Res Int. 2020;2020:9872936.

  5. Mayerova M, Ustohal L, Jarkovsky J, Pivnicka J, Kasparek T, Ceskova E. Influence of dose, gender, and cigarette smoking on clozapine plasma concentrations. Neuropsychiatr Dis Treat. 2018;14:1535-1543.

  6. Aichhorn W, Whitworth AB, Weiss EM, Marksteiner J. Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles?. Drug Saf. 2006;29(7):587-98.

  7. Ng W, Uchida H, Ismail Z, Mamo DC, Rajji TK, Remington G et al. Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study. Ther Drug Monit. 2009;31(3):360-6.

  8. Rostami-Hodjegan A, Amin AM, Spencer EP, Lennard MS, Tucker GT, Flanagan RJ. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol. 2004;24(1):70-8.

  9. Janusmed Interactions. Stockholm: Region Stockholm. 2020 [updated 2020-08-19, cited 2020-08-26.]

  10. Stockley’s Drug Interactions. London: Royal Pharmaceutical Society. 2020 [updated 2020-08-11, cited 2020-08-26.]

  11. Usall J, Suarez D, Haro JM, SOHO Study Group. Gender differences in response to antipsychotic treatment in outpatients with schizophrenia. Psychiatry Res. 2007;153:225-31.

  12. Ciapparelli A, Ducci F, Carmassi C, Carlini M, Paggini R, Catena M et al. Predictors of response in a sample of treatment-resistant psychotic patients on clozapine. Eur Arch Psychiatry Clin Neurosci. 2004;254(5):343-6.

  13. Umbricht DS, Wirshing WC, Wirshing DA, McMeniman M, Schooler NR, Marder SR et al. Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. J Clin Psychiatry. 2002;63(5):420-4.

  14. Nielsen J, Nielsen RE, Correll CU. Predictors of Clozapine Response in Patients With Treatment-Refractory Schizophrenia. J Clin Psychiatry. 2012;32(5):678-83.

  15. Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry. 1994;151(12):1744-52.

  16. Szymanski S, Lieberman J, Pollack S, Kane JM, Safferman A, Munne R et al. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics. Biol Psychiatry. 1996;39(4):249-54.

  17. Perry PJ, Miller DD, Arndt SV, Cadoret RJ. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry. 1991;148(2):231-5.

  18. Alberich S, Fernández-Sevillano J, González-Ortega I, Usall J, Sáenz M, González-Fraile E et al. A systematic review of sex-based differences in effectiveness and adverse effects of clozapine. Psychiatry Res. 2019;280:112506.

  19. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis Incidence and risk factors in the United States. N Engl J Med. 1993;329(3):162-7.

  20. Balda MV, Garay OU, Papale RM, Bignone I, Bologna VG, Brandolini A et al. Clozapine-associated neutropenia and agranulocytosis in Argentina (2007-2012). Int Clin Psychopharmacol. 2015;30(2):109-14.

  21. Hollingworth SA, Winckel K, Saiepour N, Wheeler AJ, Myles N, Siskind D. Clozapine-related neutropenia, myocarditis and cardiomyopathy adverse event reports in Australia 1993-2014. Psychopharmacology (Berl). 2018;235(7):1915-1921.

  22. Atkin K, Kendall F, Gould D, Freeman H, Liberman J, O'Sullivan D. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry. 1996;169(4):483-8.

  23. Seeman MV. Men and women respond differently to antipsychotic drugs. Neuropharmacology. 2020;163:107631.

  24. Covell NH, Weissman EM, Essock SM. Weight gain with clozapine compared to first generation antipsychotic medications. Schizophr Bull. 2004;30(2):229-40.

  25. Lau SL, Muir C, Assur Y, Beach R, Tran B, Bartrop R et al. Predicting Weight Gain in Patients Treated With Clozapine: The Role of Sex, Body Mass Index, and Smoking. J Clin Psychopharmacol. 2016;36(2):120-4.

  26. Wu RR, Zhao JP, Zhai JG, Guo XF, Guo WB. Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. J Clin Psychopharmacol. 2007;27:374-9.

  27. Meltzer HY, Perry E, Jayathilake K. Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr Res. 2003;59(1):19-27.

  28. Woosley, RL; Heise, CW; Gallo, T; Woosley, RD; and Romero, KA. QTFactors List. CredibleMeds [www]. AZCERT Inc. [cited 2020-08-31].

  29. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]

  1. Leponex (klozapin). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2019-09-22, cited 2020-08-25]
  2. Krivoy A, Gaughran F, Weizman A, Breen G, MacCabe JH. Gene polymorphisms potentially related to the pharmacokinetics of clozapine: a systematic review. Int Clin Psychopharmacol. 2016;31(4):179-84.
  3. Eiermann B, Engel G, Johansson I, Zanger UM, Bertilsson L. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol. 1997;44(5):439-46.
  4. Albitar O, Harun SN, Zainal H, Ibrahim B, Sheikh Ghadzi SM. Population Pharmacokinetics of Clozapine: A Systematic Review. Biomed Res Int. 2020;2020:9872936.
  5. Mayerova M, Ustohal L, Jarkovsky J, Pivnicka J, Kasparek T, Ceskova E. Influence of dose, gender, and cigarette smoking on clozapine plasma concentrations. Neuropsychiatr Dis Treat. 2018;14:1535-1543.
  6. Aichhorn W, Whitworth AB, Weiss EM, Marksteiner J. Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles?. Drug Saf. 2006;29(7):587-98.
  7. Ng W, Uchida H, Ismail Z, Mamo DC, Rajji TK, Remington G et al. Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study. Ther Drug Monit. 2009;31(3):360-6.
  8. Rostami-Hodjegan A, Amin AM, Spencer EP, Lennard MS, Tucker GT, Flanagan RJ. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol. 2004;24(1):70-8.
  9. Janusmed Interactions. Stockholm: Region Stockholm. 2020 [updated 2020-08-19, cited 2020-08-26.]
  10. Stockley’s Drug Interactions. London: Royal Pharmaceutical Society. 2020 [updated 2020-08-11, cited 2020-08-26.]
  11. Usall J, Suarez D, Haro JM, SOHO Study Group. Gender differences in response to antipsychotic treatment in outpatients with schizophrenia. Psychiatry Res. 2007;153:225-31.
  12. Ciapparelli A, Ducci F, Carmassi C, Carlini M, Paggini R, Catena M et al. Predictors of response in a sample of treatment-resistant psychotic patients on clozapine. Eur Arch Psychiatry Clin Neurosci. 2004;254(5):343-6.
  13. Umbricht DS, Wirshing WC, Wirshing DA, McMeniman M, Schooler NR, Marder SR et al. Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. J Clin Psychiatry. 2002;63(5):420-4.
  14. Nielsen J, Nielsen RE, Correll CU. Predictors of Clozapine Response in Patients With Treatment-Refractory Schizophrenia. J Clin Psychiatry. 2012;32(5):678-83.
  15. Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry. 1994;151(12):1744-52.
  16. Szymanski S, Lieberman J, Pollack S, Kane JM, Safferman A, Munne R et al. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics. Biol Psychiatry. 1996;39(4):249-54.
  17. Perry PJ, Miller DD, Arndt SV, Cadoret RJ. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry. 1991;148(2):231-5.
  18. Alberich S, Fernández-Sevillano J, González-Ortega I, Usall J, Sáenz M, González-Fraile E et al. A systematic review of sex-based differences in effectiveness and adverse effects of clozapine. Psychiatry Res. 2019;280:112506.
  19. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis Incidence and risk factors in the United States. N Engl J Med. 1993;329(3):162-7.
  20. Balda MV, Garay OU, Papale RM, Bignone I, Bologna VG, Brandolini A et al. Clozapine-associated neutropenia and agranulocytosis in Argentina (2007-2012). Int Clin Psychopharmacol. 2015;30(2):109-14.
  21. Hollingworth SA, Winckel K, Saiepour N, Wheeler AJ, Myles N, Siskind D. Clozapine-related neutropenia, myocarditis and cardiomyopathy adverse event reports in Australia 1993-2014. Psychopharmacology (Berl). 2018;235(7):1915-1921.
  22. Atkin K, Kendall F, Gould D, Freeman H, Liberman J, O'Sullivan D. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry. 1996;169(4):483-8.
  23. Seeman MV. Men and women respond differently to antipsychotic drugs. Neuropharmacology. 2020;163:107631.
  24. Covell NH, Weissman EM, Essock SM. Weight gain with clozapine compared to first generation antipsychotic medications. Schizophr Bull. 2004;30(2):229-40.
  25. Lau SL, Muir C, Assur Y, Beach R, Tran B, Bartrop R et al. Predicting Weight Gain in Patients Treated With Clozapine: The Role of Sex, Body Mass Index, and Smoking. J Clin Psychopharmacol. 2016;36(2):120-4.
  26. Wu RR, Zhao JP, Zhai JG, Guo XF, Guo WB. Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. J Clin Psychopharmacol. 2007;27:374-9.
  27. Meltzer HY, Perry E, Jayathilake K. Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr Res. 2003;59(1):19-27.
  28. Woosley, RL; Heise, CW; Gallo, T; Woosley, RD; and Romero, KA. QTFactors List. CredibleMeds [www]. AZCERT Inc. [cited 2020-08-31].
  29. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]